Tags : Hypereosinophilic Syndrome

GSK Reports Results of Nucala (mepolizumab) in P-III Study for

Shots: The P-III study involve assessing Nucala (300mg, q4w, SC) vs PBO in 108 adolescent and adult patients with severe HES for 32wks. The P-III study results: met its 1EPs i.e, reduction in flares with 50% fewer patients experiencing HES flare (56% vs 28%). 2EPs: 66% lower risk of first HES flare; 66% reduction in […]Read More